A Bayesian model that jointly considers comparative effectiveness research and patients’ preferences may help inform GRADE recommendations: An application to rheumatoid arthritis treatment recommendations

Publication date: Available online 16 October 2017
Source:Journal of Clinical Epidemiology
Author(s): Glen S. Hazlewood, Claire Bombardier, George Tomlinson, Deborah Marshall
ObjectiveTo estimate the preferred treatment for early rheumatoid arthritis (ERA) using a novel Bayesian approach that jointly considers patients' preferences and comparative effectiveness researchStudy Design and SettingWe estimated the preferred treatment by using patients' preferences measured in a discrete-choice experiment to apply weights to benefit and harm outcomes from a network meta-analysis, and other considerations (dosing, rare adverse events). Using Bayesian analyses, we considered the variability in patients' preferences and the imprecision in both patients' preferences and the treatment effects; all key considerations in the GRADE approach.ResultsWe estimated that most patients in our population would prefer triple therapy as initial treatment (78%) or after an inadequate response to methotrexate (62%) The probability of choosing triple therapy as initial treatment was further from 50% (the point of indifference) for more patients, making our prediction more confident, and suggesting a stronger recommendation could be made. After an inadequate response to methotrexate, the choice was more split, suggesting a decision aid may be helpful.ConclusionUsing a novel approach, we estimated that many patients with ERA may prefer triple therapy to other treatment options, in contrast to existing guidelines. This offers an approach that may help inform GRADE treatment recommendations.



from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2guvYGZ
via IFTTT